Clear All
11765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
72603-0255-01 72603-0255 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct 1, 2024 In Use
51991-0821-28 51991-0821 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Mar 5, 2021 In Use
00069-0252-30 00069-0252 Talazoparib Talzenna 0.1 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Apr 17, 2024 In Use
46026-0983-01 46026-0983 Romidepsin Istodax Chemotherapy Enzyme Inhibitor HDAC Intravenous Nov 5, 2009 May 28, 2010 No Longer Used
00078-0681-66 00078-0681 Dabrafenib Tafinlar 75.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral Apr 1, 2016 In Use
49884-0128-91 49884-0128 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Nov 29, 2022 In Use
00245-0824-30 00245-0824 Everolimus TORPENZ 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jun 24, 2024 In Use
00093-7767-24 00093-7767 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jun 10, 2020 In Use
00245-0823-30 00245-0823 Everolimus TORPENZ 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jun 24, 2024 In Use
81864-0102-30 81864-0102 Momelotinib Ojjaara 150.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Sep 15, 2023 In Use
51991-0822-33 51991-0822 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jun 5, 2023 In Use
00173-0896-01 00173-0896 Belantamab Blenrep 50.0 mg/mL Immunotherapy Drug Antibody Conjugate BCMA Intravenous Aug 5, 2020 Jun 30, 2024 No Longer Used
50242-0088-01 50242-0088 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb 22, 2013 In Use
51144-0020-01 51144-0020 ENFORTUMAB VEDOTIN PADCEV 20.0 mg/2mL Immunotherapy Drug Antibody Conjugate Nectin-4 Intravenous Dec 18, 2019 In Use
50242-0105-01 50242-0105 polatuzumab vedotin POLIVY 140.0 mg/7.52mL Immunotherapy Drug Antibody Conjugate CD79b Intravenous Jun 10, 2019 In Use
50242-0103-01 50242-0103 polatuzumab vedotin POLIVY 30.0 mg/1.88mL Immunotherapy Drug Antibody Conjugate CD79b Intravenous Sep 18, 2020 In Use
00310-4700-01 00310-4700 moxetumomab pasudotox LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Oct 24, 2018 Sep 30, 2024 No Longer Used
51144-0050-01 51144-0050 Brentuximab vedotin Adcetris 50.0 mg/10.5mL Immunotherapy Drug Antibody Conjugate CD30 Intravenous Aug 25, 2011 In Use
79952-0110-01 79952-0110 loncastuximab tesirine ZYNLONTA 10.0 mg/2mL Immunotherapy Drug Antibody Conjugate CD19 Intravenous Apr 30, 2021 In Use
73380-4700-01 73380-4700 MOXETUMOMAB PASUDOTOX LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous May 15, 2020 In Use
00074-1055-01 00074-1055 Telisotuzumab Vedotin EMRELIS 100.0 mg/mL Immunotherapy Drug Antibody Conjugate c-MET Intravenous May 14, 2025 In Use
00008-0100-01 00008-0100 Inotuzumab Ozogamicin Besponsa 0.25 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Aug 18, 2017 In Use
51144-0030-01 51144-0030 ENFORTUMAB VEDOTIN PADCEV 30.0 mg/3mL Immunotherapy Drug Antibody Conjugate Nectin-4 Intravenous Dec 18, 2019 In Use
00074-1044-01 00074-1044 Telisotuzumab Vedotin EMRELIS 20.0 mg/mL Immunotherapy Drug Antibody Conjugate c-MET Intravenous May 14, 2025 In Use
00008-4510-01 00008-4510 Gemtuzumab ozogamicin Mylotarg 5.0 mg/5mL Immunotherapy Drug Antibody Conjugate CD33 Intravenous Sep 7, 2017 In Use

Found 11765 results — Export these results